Pharmalucence gets FDA approval for generic Cardiolite

07/20/2009 | Mass High Tech (Boston)

The FDA gave radiopharmaceutical supplier Pharmalucence the green light to develop and market a generic version of Lantheus Medical Imaging's Cardiolite, a diagnostic imaging agent for coronary artery disease. Pharmalucence's product, the Kit for the Preparation of Technetium Tc-99m Sestamibi Injection, is used for identifying myocardial ischemia and infarction.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA